Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

IMRIS Inc. IMRSQ OTC

Other OTC • Healthcare • Medical - Specialties • CA • USD

SharesGrow Score
15/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

IMRIS Inc. (IMRSQ) is a Medical - Specialties company in the Healthcare sector, currently trading at $0.00. It has a SharesGrow Score of 14/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $29M, -16.1%/yr average growth. Net income is $30M (loss), growing at -18.8%/yr. Net profit margin is -105.2% (negative). Gross margin is 34.4% (+0.3 pp trend).

Balance sheet: total debt is $23M against $12M equity (Debt-to-Equity (D/E) ratio 1.99, leveraged). Current ratio is 1.1 (adequate). Debt-to-assets is 35.9%. Total assets: $65M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 17/100 (Fail), Moat 32/100 (Fail), Future ?/100 (Fail), Income 10/100 (Fail).

IMRSQ SharesGrow Score Overview

19/100
SharesGrow Score
Weak fundamentals
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 17/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 32/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — IMRSQ

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
IMRSQ: -16.1%/yr revenue is, -18.8%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✗
HEALTH Fail
17/100
Balance sheet IMRSQ: Debt-to-Equity (D/E) ratio 1.99 (leveraged), Current ratio is 1.1 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
32/100
IMRSQ: Gross margin is 34.4% (+0.3 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 32/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
IMRSQ: Net profit margin is -105.2%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.000001-0.00001
Volume38.2K
Avg Volume (30D)16.72K
Market Cap$626.00
Beta (1Y)7.79
Share Statistics
IPO Date2023-01-20
Employees121
CEOShalabh Chandra
Financial Highlights & Ratios
Revenue (TTM)$28.89M
Gross Profit$9.93M
EBITDA$-22.73M
Net Income$-30.39M
Operating Income$-23.14M
Total Cash$5M
Total Debt$23.48M
Net Debt$18.48M
Total Assets$65.48M
Price / Sales (P/S)0
Analyst Forecast
Company Info
CountryCA
ExchangeOther OTC
CurrencyUSD
ISINCA45322N1050

Price Chart

Track all markets on TradingView
IMRSQ
IMRIS Inc. ↗  ·  Other OTC
Healthcare • Medical - Specialties
0.00 52WK RANGE 0.00

People Also View

LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
 RHHBF
RHHBF
Roche Holding AG
$418.50
+1.82%
 RHHBY
RHHBY
Roche Holding AG
$51.02
+0.65%
 AZN
AZN
AstraZeneca PLC
$204.38
+1.06%
 NVSEF
NVSEF
Novartis AG
$156.48
+0.00%
 MRK
MRK
Merck & Co., Inc.
$119.96
-0.16%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message